91�鶹����ֱ��

Bleeding is the most common cause of preventable death after injury. Researchers at 91�鶹����ֱ�� and Intermountain Primary Children’s Hospital are asking for community input on whether they should participate in a study that will compare two resuscitation treatments, (whole blood versus traditional blood component therapy, and tranexamic acid versus no tranexamic acid). The goal is to compare which strategies can improve survival.

The traditional approach for treating injured patients who are bleeding is to administer multiple separate units of red blood cells, plasma and platelets — known as component therapy. However, recent evidence from military and civilian medicine suggests that survival may be better when patients receive whole blood, instead of previously separated blood products. 

Some centers also use tranexamic acid in addition to whole blood or blood components as a treatment for severe bleeding. It is not known which strategy is the best for severely injured children.

The Massive Transfusion in Children-II, or MATIC-2 trial, will compare these resuscitation strategies, in addition to all standard care, in injured children with massive bleeding.

“There is a growing body of evidence that tranexamic acid and/or whole blood may reduce the chance of dying in injured children who require blood products,” explained Katie Russell, MD, a trauma surgeon at 91�鶹����ֱ�� and Intermountain Primary Children’s Hospital.

“The standard treatment of injured patients who are bleeding involves the transfusion of different types of blood products, as well as the use of medications to help the blood clot better, along with surgery to stop the bleeding. But even with these treatments up to 30% of patients suffering from a serious traumatic injury die,” said Dr. Russell. “Finding a way to improve that survival rate is our highest priority here at Primary Children’s Hospital.”

Patients in this study will have suffered a serious and potentially life-threatening injury, causing significant blood loss, and requiring immediate lifesaving interventions. These types of injuries occur unexpectedly, and it will not be possible for most people to sign up to participate ahead of time. Most patients will be unconscious, unable to speak or hear, and too sick to consent to immediate treatment or participation in the study.

If the community feedback is positive and an independent review board (IRB) approves the study, then Primary Children’s Hospital will participate in this trial. Community members who do not want to participate can request a bracelet indicating this. If feasible, doctors will consent patients who fit the study criteria. If consent is not feasible, patients who fit the criteria will be automatically enrolled without their individual consent if they are not wearing an opt-out bracelet.

The MATIC-2 trial will be conducted in 20 leading trauma centers in the U.S. and will include 1,000 patients. The trial will begin between late 2024 and last until 2028 and is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response, within the U.S. Department of Health and Human Services under contract number 75A50123C00047.

“The results of this study have the potential to change the way trauma patients are treated,” said Dr. Russell. “If we can determine the best combination of treatments for trauma patients, we can transform the standard of care for bleeding children and save thousands of children’s lives.”

The study team members are asking for feedback from the Utah community about this study, to help determine whether the community wants this area to participate in this study.

 Please consider visiting the website below to learn more about this study and to provide your feedback to the local physicians regarding emergency research. You can do this via phone call, email, or completing a brief anonymous survey. The link to the local website is 

MATIC-2 Trial Press Release 04MAR2024